~~<i id='192E339412'><strike id='192E339412'><tt id='192E339412'><pre id='192E339412'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：explore 2025-09-06 04:38:19 - browse：25551

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Death of patient in Alzheimer’s trial raises question of possible risks

hotspot

focus

knowledge

hotspot

AdobeWhentheHumanGenomeProjectbeganin1990,bioethicistsfearedthatgivingpeopletheresultsofgenetictests

WSS

CDC concerned about possible undetected monkeypox spread in U.K.

The science behind Janet Jackson's pregnancy at 49

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

Do masks work? RCTs can't tell us

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

3 hurdles to bringing medical devices to the U.S. market

explore

hotspot

hotspot

In age of alternative facts, a scholarly course on calling out crap

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

BioMarin wins approval for gene therapy to treat hemophilia A

Transgender women dream of pregnancy via uterus transplants

Drug repurposing or repositioning? The language matters

Doctors have an ethical obligation to be advocates

Moonlake's readout produced a cash windfall. Risks remain

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Medical leaders decry Supreme Court decision on affirmative action

4 missing after record

focus

New guidelines on severe brain injury complicate already difficult decisions

4 missing after record

Disclosing genetic information: not as worrisome as once feared

Death of patient in Alzheimer’s trial raises question of possible risks

What would happen to your eyes if you looked at the solar eclipse?

Hundreds of thousands march in Israel. Former security chiefs beg Netanyahu to halt legal overhaul

knowledge

knowledge

hotspot

hotspot